Medicines optimisation


To ensure patients with Atrial Fibrillation (AF) in North West London receive the right medication at the right time, improving health outcomes and efficiency savings.

This means that:

  • AF patients receive NICE-recommended treatment and interventions
  • Best practice in medication management is diffused amongst clinicians and patients
  • Patient are better supported to self-manage their conditions


There is strong evidence that NHS resources are wasted due to poor prescribing behaviour and medication adherence. Quality and Outcomes data (2013/2014) demonstrates that over 4,300 patients with identified Atrial Fibrillation (AF) in NWL and at a high risk of stroke are not on the anticoagulation treatment recommended by NICE guidelines. Public Heath England also estimates that there may be an additional 17,000 unidentified AF patients in the region. Our programme aims to address this issue.


Atrial Fibrillation (AF)
  • Work with the pan-London Interdisciplinary Group for
    Stoke prevention in Atrial Fibrillation (iSPAF) to ensure
    AF patients get the appropriate intervention
  • Develop a new pathway experience for AF patients,
    enabled by new technologies

One of our outputs has also been a series of Atrial Fibrillation (AF) Innovation Workshops for North West London. Each workshop was delivered as a day-long session designed to run through the AF pathway in bite-sized chunks from early stage detection, through to diagnosis, selecting the right anticoagulant and living with the condition. Underpinning all these themes was how innovation can assist in bringing high levels of quality to AF treatment in NW London.

Read more about our Atrial Fibrillation workshops here

Desired outcomes

  • Improved staff understanding of best practice anti-coagulation services, delivery and measurement
  • Improved AF detection and warfarin anti-coagulation
  • 250 strokes and 60 stroke-related deaths prevented per year
  • Use of innovations accelerated through work with industry, SMEs, ABPI and SBRI
  • Knowledge of successful, evidence-based anti-coagulation services successfully diffused
  • £2 million savings generated annually (cost associated with the cost of treating strokes in NWL)